Close Menu

NEW YORK – Becton Dickinson reported an 11 percent year-over-year decrease in its fiscal third quarter revenues on Thursday due to impacts of the ongoing COVID-19 pandemic.

For the three months ended June 30, the medical technology company posted $3.86 billion in revenues, down from $4.35 billion in the year-ago quarter and below the average analyst estimates of $3.94 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.